Related Experiment Video
Updated: Dec 5, 2025

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
Targeting myocardial ischaemic injury in the absence of reperfusion
M V Basalay1, D M Yellon1, S M Davidson2
1The Hatter Cardiovascular Institute, 67 Chenies Mews, London, WC1E 6HX, UK.
Insights
Preventing myocardial ischaemic injury, distinct from reperfusion injury, involves strategies to preserve ATP or enhance blood supply. Therapies targeting inflammation and promoting myocardial regeneration offer future potential for limiting heart damage.
Area of Science:
- Cardiovascular Science
- Ischaemic Heart Disease
- Myocardial Protection
Background:
- Sudden myocardial ischaemia causes acute coronary syndrome, often leading to ST-elevation myocardial infarction (STEMI).
- Microvascular obstruction (MVO) prevents full blood flow restoration in up to two-thirds of STEMI patients, leaving ischaemic myocardium.
- Existing cardioprotective strategies primarily target reperfusion injury, not the initial ischaemic insult.
Purpose of the Study:
- To investigate methods for specifically preventing ischaemic myocardial injury, particularly in chronic coronary artery occlusion models.
- To explore interventions that limit infarct size by addressing the primary ischaemic event.
Main Methods:
- Review of experimental strategies to prevent ischaemic injury.
- Categorization of interventions into those preserving ATP (reducing oxygen consumption) and those increasing oxygen/blood supply.
- Consideration of methods for assessing infarct size in the absence of reperfusion.
Main Results:
- Interventions preserving ATP include hypothermia, cardiac unloading, reduced heart rate/contractility, and ischaemic preconditioning.
- Interventions increasing oxygen supply involve collateral vessel dilation.
- Therapies stimulating new collateral formation can limit ischaemic injury.
- Targeting inflammation and promoting myocardial regeneration are potential future strategies.
Conclusions:
- Preventing ischaemic injury requires distinct strategies from managing reperfusion injury.
- Enhancing collateral circulation is a key approach to limiting infarct size during ischaemia.
- Future research should focus on interventions that promote myocardial regeneration and prevent adverse remodelling.
Abstract:
Sudden myocardial ischaemia causes an acute coronary syndrome. In the case of ST-elevation myocardial infarction (STEMI), this is usually caused by the acute rupture of atherosclerotic plaque and obstruction of a coronary artery. Timely restoration of blood flow can reduce infarct size, but ischaemic regions of myocardium remain in up to two-thirds of patients due to microvascular obstruction (MVO). Experimentally, cardioprotective strategies can limit infarct size, but these are primarily intended to target reperfusion injury. Here, we address the question of whether it is possible to specifically prevent ischaemic injury, for example in models of chronic coronary artery occlusion. Two main types of intervention are identified: those that preserve ATP levels by reducing myocardial oxygen consumption, (e.g. hypothermia; cardiac unloading; a reduction in heart rate or contractility; or ischaemic preconditioning), and those that increase myocardial oxygen/blood supply (e.g. collateral vessel dilation). An important consideration in these studies is the method used to assess infarct size, which is not straightforward in the absence of reperfusion. After several hours, most of the ischaemic area is likely to become infarcted, unless it is supplied by pre-formed collateral vessels. Therefore, therapies that stimulate the formation of new collaterals can potentially limit injury during subsequent exposure to ischaemia. After a prolonged period of ischaemia, the heart undergoes a remodelling process. Interventions, such as those targeting inflammation, may prevent adverse remodelling. Finally, harnessing of the endogenous process of myocardial regeneration has the potential to restore cardiomyocytes lost during infarction.

